| Fund ID | 805-2778306763 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | Yes |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | No |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 22% |
| Owned by the adviser or related persons | 7% |
| Owned by funds of funds | 75% |
| Owned by non-U.S. persons | 45% |
| Fund | Type | Gross assets |
|---|---|---|
| US Research Equity Extended Master Fund (cayman) L.P. | Hedge | $6.62B |
| Global Research Equity Extended Master Fund (cayman), L.P. | Hedge | $6.51B |
| Iguazu Master Investors (cayman) L.P. | Hedge | $5.88B |
Wellington Biomedical Innovation Master Investors (cayman) II L.P. reports $477.2 million in gross assets, among the top 15% of private funds by size.
Wellington Biomedical Innovation Master Investors (cayman) II L.P. is managed by Wellington Alternative Investments LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.